Genetic Analysis AS (XSAT: GEAN)
Health Care · Biotechnology · NO
Nkr0.48
-9.43% today · -35.4% 1Y
Genetic Analysis AS (XSAT: GEAN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.82M.
Over the last twelve months the share price has lost 35.4%, trading between 0.42 and 0.90.
Tweenvest scores Genetic Analysis AS across four factors: quality 47/100, value 66/100, growth 75/100. Its strongest factor is growth.
GEAN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.82M
- Revenue (TTM)
- $2.05M
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- 2.06
- 52-week high
- Nkr0.90
- 52-week low
- Nkr0.42
- Avg volume (3M)
- —
- Shares outstanding
- 69.09M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Predilife S.A.ENXTPA: ALPRE | $4.02M | €0.91 | -0.44% |
| Tecnovatica S.A.WSE: TEC | $4.00M | zł0.44 | -0.45% |
| Calidi Biotherapeutics, Inc.NYSEAM: CLDI | $3.99M | $1.01 | -6.48% |
| Biotron LimitedASX: BIT | $3.87M | AU$0.00 | -20.00% |
| Tissue Repair LtdASX: TRP | $3.78M | AU$0.09 | +9.76% |
| Eocene Ltd.NasdaqCM: EOCN | $3.76M | $3.46 | -4.22% |
| Bharat Immunologicals & Biologicals Corporation LimitedBSE: 524663 | $3.67M | Rs8.18 | -37.13% |
| StageZero Life Sciences Ltd.TSXV: SZLS.H | $3.64M | CA$— | — |
Figures last refreshed Oct 4, 2026.